Efficacy and safety of Xingnaojing as an adjuvant therapy for thrombolysis in the treatment of acute ischemic stroke： A meta-analysis
10.19845/j.cnki.zfysjjbzz.2026.0038
- VernacularTitle:醒脑静辅助溶栓治疗急性缺血性脑卒中的有效性及安全性的Meta分析
- Author:
Yanqin HU
1
;
Mingfen WU
1
Author Information
1. Department of Pharmacy， Beijing Tiantan Hospital， Capital Medical University， Beijing 100070， China
- Publication Type:Journal Article
- Keywords:
Alteplase;
Xingnaojing injection;
Serum inflammatory factors;
Response rate;
Acute ischemic stroke
- From:
Journal of Apoplexy and Nervous Diseases
2026;43(3):219-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the effect of Xingnaojing injection on the levels of inflammatory factors in patients with acute ischemic stroke （AIS） as an adjuvant therapy for intravenous thrombolysis with alteplase， and to investigate the neuroprotective significance of Xingnaojing injection. Methods Chinese databases （CNKI， Wanfang Data， and VIP） and English databases （PubMed， Embase， and the Cochrane Library） were searched for studies on the serum levels of inflammatory factors in the treatment of AIS published up to August 2024， and the patients were divided into control group and experimental group based on the method of randomized controlled trial （RCT）. The patients in the control group received intravenous thrombolysis with alteplase， while those in the experimental group received intravenous thrombolysis with alteplase combined with Xingnaojing injection. The Cochrane Collaboration Risk of Bias Tool was used to assess the methodological quality of the studies included for analysis， and RevMan 5.3 software was used to conduct a meta-analysis on NIHSS， response rate， C-reactive protein （CRP）， TNF-α， IL-6， IL-8， IL-1， and adverse reactions for the experimental group and the control group. Results A total of 19 RCTs were included， involving 1 711 patients （856 in the experimental group and 855 in the control group）. The meta-analysis showed that there were significant differences between the two groups in NIHSS （SMD=-2.12，95%CI -2.74 to -1.50， P<0.001）， response rate （OR=5.22， 95%CI 3.44‒7.91， P<0.001）， CRP （SMD=-1.27， 95%CI -1.74 to -0.79， P<0.001），TNF-α（SMD=-2.91， 95%CI -3.74 to -2.08， P<0.001）， IL-6 （SMD=-6.74， 95%CI -9.06 to -4.41， P<0.001），IL-8 （SMD=-4.85，95%CI -6.49 to -3.20， P<0.001）， IL-1 （SMD=-4.89，95%CI -6.86 to -2.92， P<0.001）， and adverse reactions （OR=0.41， 95%CI 0.26-0.64， P<0.001）. Conclusion As an adjuvant therapy for thrombolysis with alteplase， Xingnaojing injection significantly reduces the levels of inflammatory factors in AIS patients and exerts a neuroprotective effect on brain cells， with a high response rate and few adverse reactions， which provides a safe and reliable reference for clinical practice.
- Full text:2026061009031116591醒脑静辅助溶栓治疗急性缺血性脑卒中的有效性及安全性的Meta分析.pdf
